Authorized purpose: Analyzes frontal chest X-ray images for pneumothorax to enable passive case prioritization or triage in PACS or a workstation.
Clinical role
Notification-only triage that checks frontal chest X-ray suitability, detects pneumothorax, and flags those images in the PACS/workstation for prioritized radiologist review, providing no diagnostic information beyond the notification.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: Notification only, not diagnostic or standalone; does not replace physician review and is limited to adult-size patients.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Analyzes frontal chest X-ray images for pneumothorax to enable passive case prioritization or triage in PACS or a workstation.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Frontal chest X-rays subject to age, view, and lung-field validation.
Who uses it?Intended users: Qualified physicians and radiologists.
What does the software produce?Output: A passive PACS or worklist flag with optional DICOM Secondary Capture, without original-image markup.
What is its most important limitation?Key limitation: Notification only, not diagnostic or standalone; does not replace physician review and is limited to adult-size patients.
Clinical takeaway. Clinical role: Analyzes frontal chest X-ray images for pneumothorax to enable passive case prioritization or triage in PACS or a workstation.
Evidence takeaway. Evidence from the reviewed source record: Reported AUC 0.9607 (95% CI 0.9491-0.9724), sensitivity 84.3%, and specificity 93.5%, with subgroup results for large and small pneumothorax.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Analyzes frontal chest X-ray images for pneumothorax to enable passive case prioritization or triage in PACS or a workstation.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Notification-only triage that checks frontal chest X-ray suitability, detects pneumothorax, and flags those images in the PACS/workstation for prioritized radiologist review, providing no diagnostic information beyond the notification.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Critical Care Suite is intended for notification only and does not provide diagnostic information beyond the notification." … "analysis algorithms to identify pre‐specified critical findings (pneumothorax) in frontal chest X‐ray images and flag the images in the PACS/workstation to enable prioritized review by the radiologist.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Reported AUC 0.9607 (95% CI 0.9491-0.9724), sensitivity 84.3%, and specificity 93.5%, with subgroup results for large and small pneumothorax.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Critical Care Suite 2.0 regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested version1
IndependenceIndependence not established
K183182
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K183182. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Frontal chest X-rays subject to age, view, and lung-field validation.
Scope: Exact FDA submission. FDA packet input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Critical Care Suite as a software module deployable on computing and X-ray imaging platforms such as Digital Projection Radiographic Systems (for example Optima XR240amx, running automatically after image acquisition), PACS, on premise or on cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Critical Care Suite is designed as a software" … "computing and X-ray imaging platforms such as Digital Projection Radiographic Systems, PACS, On Premise or On Cloud.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: A passive PACS or worklist flag with optional DICOM Secondary Capture, without original-image markup.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Critical Care Suite as a software module deployable on computing and X-ray imaging platforms such as Digital Projection Radiographic Systems (for example Optima XR240amx, running automatically after image acquisition), PACS, on premise or on cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Critical Care Suite is designed as a software" … "computing and X-ray imaging platforms such as Digital Projection Radiographic Systems, PACS, On Premise or On Cloud.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.
The 510(k) summary states Critical Care Suite is intended for notification only and is not intended to replace the review of the x-ray image by a qualified physician.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.
ACR AI Central provides an exact-submission model card for Critical Care Suite; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K183182 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.